Niva RussekBlum - NeuroSense Therapeutics Chief Officer
| NRSNW Stock | USD 0.15 0 3.13% |
Executive
Niva RussekBlum is Chief Officer of NeuroSense Therapeutics Ltd
| Age | 45 |
| Address | Building B, Herzliya, Israel, 4672562 |
| Phone | 972 9 799 6183 |
| Web | https://www.neurosense-tx.com |
NeuroSense Therapeutics Management Efficiency
The company has return on total asset (ROA) of (1.5079) % which means that it has lost $1.5079 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (4.9484) %, meaning that it generated substantial loss on money invested by shareholders. NeuroSense Therapeutics' management efficiency ratios could be used to measure how well NeuroSense Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, NeuroSense Therapeutics' Return On Capital Employed is fairly stable compared to the past year. Return On Equity is likely to climb to 5.66 in 2024, whereas Return On Tangible Assets are likely to drop (3.34) in 2024. At this time, NeuroSense Therapeutics' Total Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to climb to about 23.4 K in 2024, whereas Other Current Assets are likely to drop slightly above 97 K in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Petra Pesendorfer | Valneva SE ADR | 38 | |
| Patrick Fowler | Vericel Corp Ord | N/A | |
| Julie CCRP | DiaMedica Therapeutics | 50 | |
| Maple MD | Equillium | N/A | |
| Tyler Nielsen | Denali Therapeutics | 46 | |
| Frederic Jacotot | Valneva SE ADR | 60 | |
| Roland DeAngelis | Vericel Corp Ord | N/A | |
| Chris Walsh | Denali Therapeutics | N/A | |
| John Leonard | Vaccinex | 77 | |
| Laura Hansen | Denali Therapeutics | N/A | |
| Ernest Smith | Vaccinex | 52 | |
| Sean Flynn | Vericel Corp Ord | 50 | |
| Jill CPA | Vaccinex | 52 | |
| Michael Moore | Equillium | N/A | |
| Mike Gilligan | Vericel Corp Ord | N/A | |
| Franck MBA | Valneva SE ADR | 57 | |
| Chris JD | Denali Therapeutics | N/A | |
| Rashieda Gluck | Dianthus Therapeutics | N/A | |
| Matthew Ritter | Equillium | N/A | |
| Peter Buhler | Valneva SE ADR | 53 | |
| Mark Rowen | Denali Therapeutics | N/A | |
Management Performance
| Return On Equity | -4.95 | ||||
| Return On Asset | -1.51 |
NeuroSense Therapeutics Leadership Team
Elected by the shareholders, the NeuroSense Therapeutics' board of directors comprises two types of representatives: NeuroSense Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NeuroSense. The board's role is to monitor NeuroSense Therapeutics' management team and ensure that shareholders' interests are well served. NeuroSense Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NeuroSense Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ferenc Tracik, Chief Officer | ||
| Or Eisenberg, Chief Officer | ||
| Yael Barak, VP Compliance | ||
| Alon BenNoon, CEO CoFounder | ||
| Hagit Binder, Chief Officer | ||
| Oron DVM, Chief Officer | ||
| Ferenc MD, Chief Officer | ||
| Shiran Zimri, Head Program | ||
| Keren Pushett, Head HR | ||
| Avital Pushett, Head Program | ||
| Eidan Loushi, CRA | ||
| Niva RussekBlum, Chief Officer |
NeuroSense Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is NeuroSense Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -4.95 | ||||
| Return On Asset | -1.51 | ||||
| Number Of Shares Shorted | 2.21 K | ||||
| EBITDA | (10.63 M) | ||||
| Net Income | (11.28 M) | ||||
| Cash And Equivalents | 994 K | ||||
| Cash Per Share | 0.13 X | ||||
| Total Debt | 142 K | ||||
| Current Ratio | 8.08 X | ||||
| Book Value Per Share | (0.09) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for NeuroSense Stock Analysis
When running NeuroSense Therapeutics' price analysis, check to measure NeuroSense Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeuroSense Therapeutics is operating at the current time. Most of NeuroSense Therapeutics' value examination focuses on studying past and present price action to predict the probability of NeuroSense Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeuroSense Therapeutics' price. Additionally, you may evaluate how the addition of NeuroSense Therapeutics to your portfolios can decrease your overall portfolio volatility.